HRTX

Peraza Lisa

Known title: VP, Chief Accounting OfficerCIK: 0001828266

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.

this person other insiders at HRTX

Transaction History

HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$2K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$619
HRTX▲ Buy—
HRTX▼ Sell$22K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$1K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$2K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$3K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$3K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$3K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$5K
HRTX▲ Buy—
HRTX▲ Buy—
HRTX▼ Sell$8K
HRTX▼ Sell$2K
HRTX▲ Buy—

We use analytics to understand how market-wall is used. No personal data is sold.